A reporter's PressPass is required to access this story until the embargo expires on 16-Oct-2018 9:00 AM EDT
The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please do so. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.
Tamara Strauss has been living with high-grade, stage IV pancreatic neuroendocrine cancer for more than three years. Current treatments, although effective for her, are highly toxic. Tamara enrolled in a first-of-its-kind, pilot study at Moores Cancer Center at UC San Diego Health to test a personalized vaccine using her unique cancer mutations to boost an anti-tumor immune response.
For decades, scientists have been trying to develop a vaccine that prevents mosquitoes from spreading malaria among humans. This unique approach — in which immunized humans transfer anti-malarial proteins to mosquitoes when bitten — is called a transmission-blocking vaccine (TBV). A new biotech advancement moves us closer to this goal. If successful, it could help reduce the spread of the disease, which kills more than 400,000 people annually.